Types of Research
- (-) Remove Literature Review filter Literature Review
- (-) Remove 2017 filter 2017
- (-) Remove Agricultural Inputs & Farm Management filter Agricultural Inputs & Farm Management
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove 2015 filter 2015
- (-) Remove 2019 filter 2019
- (-) Remove Data Analysis filter Data Analysis
- (-) Remove 2008 filter 2008
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
Common estimates of agricultural productivity rely upon crude measures of crop yield, typically defined as the weight harvested of a crop divided by the area harvested. But this common yield measure poorly reflects performance among farm systems combining multiple crops in one area (e.g., intercropping), and also ignores the possibility that farmers might lose crop area between planting and harvest (e.g., partial crop failure). Drawing on detailed plot-level data from Tanzania’s National Panel Survey, our research contrasts measures of smallholder productivity using production per hectare harvested and production per hectare planted.
An initial analysis (Research Brief - Rice Productivity Measurement) looking at rice production finds that yield by area planted differs significantly from yield by area harvested, particularly for smaller farms and female-headed households. OLS regression further reveals different demographic and management-related drivers of variability in yield gains – and thus different implications for policy and development interventions – depending on the yield measurement used. Findings suggest a need to better specify “yield” to more effectively guide agricultural development efforts.
This brief reviews the evidence of realized yield gains by smallholder farmers attributable to the use of high-quality seed and/or improved seed varieties. Our analysis suggests that in most cases, use of improved varieties and/or quality seed is associated with modest yield increases. In the sample of 395 trials reviewed, positive yield changes accompanied the use of improved variety or quality seed, on average, in 10 out of 12 crops, with rice and cassava as the two exceptions.